Zymeworks (ZYME) announced the appointment of Scott Platshon as acting chief investment officer. Platshon will report directly to Zymeworks’ chair and CEO, Kenneth Galbraith, and work closely with him to manage expected future cash flows from Ziihera and other healthcare assets and licensed product candidates, such as pasritamig, which is being advanced to Phase 3 registration studies by Johnson & Johnson Innovative Medicine. He will also manage the operational execution of Zymeworks’ healthcare asset aggregation strategy. Concurrent with this appointment, Platshon has stepped down from the company’s board of directors. As this is a part-time role, he will also continue to serve as a Partner at EcoR1 Capital, a biotech-focused investment fund.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks Stock (ZYME) Soars on Positive Results for Cancer Drug Ziihera, Top Analysts Boost Price Targets
- Zymeworks Stock Upgraded to ‘Buy’ on Promising Phase 3 Trial Results and Financial Prospects
- Zymeworks price target raised to $42 from $30 at Jefferies
- Zymeworks price target raised to $37 from $24 at Leerink
- Zymeworks’ Promising Clinical Trial Results and Market Potential Justify Buy Rating